Summary: In most software markets, usage data is primarily a commercial tool; a signal for renewals, upsells, and churn prevention. In medical device software, it is more than that. Usage patterns reveal not just how customers interact with a product, but how clinicians rely on it, which diagnostic capabilities deliver measurable value, and whether deployments are operating within the boundaries of regulatory approval. The vendors that treat post-deployment data as a first-class asset are building a fundamentally different kind of business.
—
Most medical device software companies know a lot about what their products do before they ship. They know how the algorithms perform in validation tests, which features come with each release, and how the device should behave in a controlled clinical environment.
What they often know far less about is what happens after deployment.
Which features are clinicians actually using? Which AI models are running the most diagnoses? Which hospital sites have drifted into non-compliant configurations? Which customers are about to churn, and which are ready for a feature upgrade?
These questions sit at the intersection of product performance, regulatory assurance, and commercial growth. The discipline that answers them is usage intelligence. Yet many medical device vendors still lack a systematic way to collect, analyze, and act on this data.
What Usage Intelligence Means in a Medical Software Context
Usage intelligence is a structured dataset that provides insights into how a product is actually used in the field. In a medical device environment, this would include information such as feature usage, product adoption, entitlements (i.e., which users can access what), seat (user) activations, and time-to-value of a new implementation.
This data provides visibility into how customers interact with a product at the account level: which capabilities are used regularly, which remain dormant, and how usage evolves over time.
In pure SaaS environments, collecting this data is relatively straightforward. Applications run in the cloud, telemetry flows continuously, and product teams can monitor usage patterns in near real time.
The conditions under which medical device software is used are quite different.
For example, the device might often be installed in a completely air-gapped environment within a hospital or clinic. There are strict privacy regulations around what data can leave the system and who is allowed access to it. And finally, there is an additional level of complexity in what the data is measuring and how representative patient, user, or employee data may be, which means that raw interpretation is not always indicative of real-world value.
But these constraints do not reduce the importance of usage intelligence; they increase it.
Medical software companies must find ways to collect data locally, aggregate it appropriately, and transmit it without compromising patient data. When done properly, data can be used to prove product effectiveness, confirm regulatory compliance, and gain a clear understanding of commercial success.
Usage Intelligence at the Intersection of Clinical and Commercial Value
For companies delivering AI-driven medical software, usage intelligence lies at the intersection of clinical impact and business performance.
Consider an AI cancer-detection company deploying diagnostic software across hospitals worldwide. The company sells primarily through partner channels, which means the vendor is one step removed from the clinicians actually using the technology.
Without visibility into usage data flowing back from those environments, the vendor faces a significant blind spot. They can track licenses sold to distributors, but they cannot easily see how frequently AI is used, which diagnostic features are most often invoked, or how adoption varies across hospitals.
By implementing structured usage monitoring across both direct and partner-based deployments, the company can gain visibility into how clinicians interact with the AI across its global footprint. It provides operational insight into how the product is performing clinically.
When the data shows that AI-assisted screening enables significantly more patients to be screened earlier, that information becomes a powerful validation signal for the product itself.
It also strengthens the commercial narrative. Demonstrating measurable clinical adoption supports renewal conversations with hospital customers and helps partners position the technology more effectively in new markets.
From Zero Visibility to Data-Driven Roadmap Decisions
The value of usage intelligence, as facilitated by licensing and entitlements, is not limited to commercial operations. It also changes how product decisions get made.
For many medical device startups, the revelation of usage intelligence illustrates that they simply do not know how their software is being used once it leaves their environment.
One medical AI diagnostics company experienced exactly this situation during its early growth phase. The organization had developed sophisticated imaging analysis tools but lacked a data-monitoring system to observe how customers used those capabilities after deployment.
Once usage monitoring and entitlement checks were in place to ensure users could only use the features appropriate to their account type, the changes came quickly. For the first time, the team could view product usage traffic across its installed base. They could identify which features clinicians relied on most frequently and which were rarely used.
This insight had an immediate effect on how product decisions were made.
Instead of relying primarily on engineering intuition or customer anecdotes, product teams could evaluate actual usage patterns. If one diagnostic capability consistently generated high clinical adoption, it became a priority for further development. If another feature showed minimal engagement, the team could reassess its place in the roadmap.
In this sense, usage intelligence becomes a practical data practice. Standardized event schemas track activations and feature usage, and the resulting insights are routed to the teams responsible for pricing, packaging, and product development.
In medical environments, however, this intelligence must always be collected with privacy by design. Systems must aggregate data where possible, minimize exposure of personally identifiable information, and ensure that hospitals retain control over how operational data is shared.
The goal is not surveillance of clinical activity, but a clear, privacy-respecting view of how the product performs in real-world environments.
Closing the Feedback Loop: From Data to Decision to Renewal
When usage intelligence is implemented effectively, it creates a continuous feedback loop between product behavior and business outcomes.
Product teams use the data to guide roadmap investments. Customer success teams monitor adoption signals to identify accounts that may need additional support. Sales teams use usage insights to recognize expansion opportunities when customers approach feature limits or demonstrate strong engagement.
Marketing teams can also draw on usage patterns to build more accurate customer narratives. Understanding what capabilities clinicians rely on (and when they use them) allows vendors to communicate value with far greater precision.
With complex distribution models where multiple devices are sold, usage information also helps vendors understand who is actually using their products. End-user registration information can provide a clear picture of product usage that would otherwise go unnoticed, converting, thus, operations into strategic decision-making.
The Next Phase of Software-Led Medical Devices
The shift from hardware-centric medical devices to software-driven platforms is already well underway. Diagnostic imaging systems, AI-assisted screening tools, and connected surgical devices increasingly rely on software capabilities to deliver clinical value.
The next shift is now emerging: from software-led devices to intelligence-led platforms.
Those companies that instrument their deployments well, respect the privacy requirements of the clinical environment, and establish closed-loop feedback between usage data and product development will gradually build their advantage.
Each diagnosis, each feature, each renewal won or lost creates a signal. Over time, those signals form one of the most valuable assets a medical device company can possess. But only if the organization is listening. And only if the data is easily accessible.
